CYTK - Conference and earnings call announcements

SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of the Company management team will participate in the following investor conferences in June: 2026 Jefferies Global Healthcare Conference: Fireside chat on Wednesday, June 3, 2026 at 8:10 AM Eastern Time in New York, NY.Goldman Sachs 47th Annual Global Healthcare Conference: Fireside chat on Monday, June 8, 2026 at 9:20 AM Eastern Time in Miami Beach, FL. Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at https://ir.cytokinetics.com/. The webcast replays will be archiv

SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of the Company management team will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 at 3:35 PM Eastern Time in New York, NY. Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at https://ir.cytokinetics.com/. The webcast replays will be archived on the Cytokinetics website for 90 days following the conclusion of the event. About Cytokinetics Cytokinetics is a specialty cardiovascular biopharmaceutical co

SOUTH SAN FRANCISCO, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of the Company's management team are scheduled to participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 1:30 PM Eastern Time. Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event. About Cytokinetics Cytokinetics is a specialty cardiovascular biopharmaceutical compan

SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of the Company management team will participate in the following investor conferences in March: Leerink 2026 Global Healthcare Conference: Fireside chat on Monday, March 9, 2026 at 9:20 AM Eastern Time in Miami Beach, FL.Citizens 2026 Life Sciences Conference: Fireside chat on Tuesday, March 10, 2026 at 9:00 AM Eastern Time in Miami Beach, FL.2026 Jefferies Biotech on the Beach Summit: One-on-one meetings on Wednesday, March 11, 2026 in Miami Beach, FL.Barclays 28th Annual Global Healthcare Conference: Fireside chat on Wednesday, March 11, 2026 at 2:30 PM E

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 AM Pacific Time in San Francisco, CA. Interested parties may access the live webcast of the presentation by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event. About Cytokinetics Cytokinetics is a specialty cardiovascular biopharmaceutical

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of the Company management team will participate in the following investor conferences in November: Stifel 2025 Healthcare Conference: Fireside chat on Tuesday, November 11, 2025 at 11:20 AM Eastern Time in New York, NY.Jefferies Global Healthcare Conference: Fireside chat on Monday, November 17, 2025 at 2:30 PM Greenwich Mean Time in London, England. Interested parties may access the live webcasts of the fireside chats by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replays will be archived o

SOUTH SAN FRANCISCO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of the Company's management team are scheduled to present a corporate update at the Stifel 2025 Virtual Cardiometabolic Forum on Tuesday, September 30, 2025 at 10:00 AM Eastern Time. Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event. About Cytokinetics Cytokinetics is a specialty cardiovascular biopharmaceutical company, buil

Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Journal of the American College of Cardiology New Analysis Shows Annual Incidence Rate of Atrial Fibrillation with Aficamten is 1.5%, Consistent with Expected Rates in Prediction Model of Patients with HCM; Simultaneous Publication in Heart Rhythm Longer-Term Data Presented Consistent with Previously Reported Safety Profile of Aficamten Company to Host Investor Event and Webcast Tuesday September 2, 2025, at 8:30 AM Eastern Time SOUTH SAN FRANCISCO, Calif., Aug. 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announc

Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol Primary Endpoint Result Consistent Across All Prespecified Subgroups Company to Host Investor Event and Webcast Tuesday September 2, 2025, at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., Aug. 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that primary results from MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM) were presented in a Hot Line Session at the European Society of Cardiology Congress 2025 in Madrid, Spain, and simultaneously published in The New England Journal of Medicine.1 MAPLE-HCM is

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of the Company management team will participate in the following investor conferences in September: Citi's 2025 BioPharma Back to School Conference: Fireside chat on Tuesday, September 2, 2025 at 2:30 PM Eastern Time in Boston, MA.2025 Wells Fargo Healthcare Conference: Fireside chat on Wednesday, September 3, 2025 at 11:00 AM Eastern Time in Everett, MA.Cantor Global Healthcare Conference 2025: Fireside chat on Thursday, September 4, 2025 at 2:45 PM Eastern Time in New York, NY.Morgan Stanley 23rd Annual Global Healthcare Conference: Fireside chat on Tuesda

Positive Results from MAPLE-HCM to be Shared in Hot Line Presentation Late Breaking Clinical Science Session to Present Incidence and Impact of Atrial Fibrillation Across Three Clinical Trials of Aficamten in Obstructive Hypertrophic Cardiomyopathy Company to Host Investor Event and Webcast Tuesday September 2, 2025, at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced five presentations related to aficamten at the European Society of Cardiology Congress 2025 taking place in Madrid, Spain from August 29, 2025 – September 1, 2025 including a Hot Line presentation of the primary results

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of the Company's management team are scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 9:20 AM Eastern Time at the New York Marriott Marquis Hotel in New York, NY. Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event. About Cytokinetics Cytokinetics is a special

SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the Company is scheduled to participate in the following investor conferences in May: The Citizens Life Sciences Conference: Members of the management team will participate in a fireside chat on Wednesday, May 7, 2025 at 10:00 AM Eastern Time at the New York Hilton Midtown Hotel in New York, NY.2025 RBC Capital Markets Global Healthcare Conference: Members of the management team will participate in a fireside chat on Wednesday, May 21, 2025 at 8:30 AM Eastern Time at the InterContinental New York Barclay Hotel in New York, NY. Interested parties may access the liv

SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of the Company's management team are scheduled to participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 2:15 PM Eastern Time. Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event. About Cytokinetics Cytokinetics is a specialty biopharmaceutical company building on it

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the company is scheduled to participate in the following investor conferences in March: Leerink Global Biopharma Conference: Robert I. Blum, President and Chief Executive Officer, and Andrew Callos, Executive Vice President and Chief Commercial Officer, will participate in a fireside chat on Monday, March 10, 2025 at 11:20 AM Eastern Time at the W South Beach Hotel in Miami Beach, FL.Jefferies Biotech on the Beach Summit: Management will participate in one-on-one meetings on Tuesday, March 11, 2025 at the Ritz Carlton South Beach Hotel in Miami Beach, FL.Barclays 2

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025 at 4:40 PM Eastern Time. Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event. About Cytokinetics Cytokinetics is a late-stage, m

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:00 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco, CA. Interested parties may access the live webcast of the presentation by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event. About Cytokinetics Cytokinet

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the Company is scheduled to participate in the following December investor conferences: 7th Annual Evercore ISI HealthconX Conference: Cytokinetics will participate in a fireside chat on Tuesday, December 3, 2024 at 9:35 AM Eastern Time at the Loews Coral Gables Hotel in Coral Gables, FL.36th Annual Piper Sandler Healthcare Conference: Cytokinetics will participate in a fireside chat on Wednesday, December 4, 2024 at 8:00 AM Eastern Time at the Lotte New York Palace in New York, NY. Interested parties may access the live webcasts of the fireside chats by visiting t

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the Company is scheduled to participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 4:00 PM Greenwich Mean Time at The Waldorf Hilton Hotel in London, England. Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event. About Cytokinetics Cytokinetics is a late-stage, specialty cardio

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the Company is scheduled to participate in the following investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference: Cytokinetics will participate in a fireside chat on Wednesday, September 4, 2024 at 7:45 AM Eastern Time at the New York Marriott Marquis Hotel in New York, NY.H.C. Wainwright 26th Annual Global Investment Conference: Cytokinetics will present on Monday, September 9, 2024 at 10:30 AM Eastern Time at the Lotte New York Palace Hotel in New York, NY.Cantor Fitzgerald Global Healthcare Conference 2024: Cytokinetics will par

SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the company is scheduled to participate in the following investor conferences in June: Jefferies Global Healthcare Conference: Robert I. Blum, President and Chief Executive Officer, and Andrew Callos, Executive Vice President and Chief Commercial Officer, will participate in a fireside chat on Wednesday, June 5, 2024 at 2:00 PM Eastern Time at the New York Marriott Marquis Hotel in New York, NY.45th Annual Goldman Sachs Healthcare Conference: Robert I. Blum, President and Chief Executive Officer, and Andrew Callos, Executive Vice President and Chief Commercial Office

SOUTH SAN FRANCISCO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024 at 2:15 PM Eastern Time. Interested parties may access the live webcast of this fireside chat by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event. About Cytokinetics Cytokinetics is a late-stage, specialty cardiovascular

SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the company is scheduled to participate in the following investor conferences in March: Leerink Global Biopharma Conference: Robert I. Blum, President and Chief Executive Officer, Andrew Callos, Executive Vice President and Chief Commercial Officer, and Fady I. Malik, Executive Vice President of Research & Development, will participate in a fireside chat on Monday, March 11, 2024 at 1:20 PM Eastern Time at the Fontainebleau Miami Beach Hotel in Miami Beach, FL.Jefferies Biotech on the Bay Summit: Management will participate in one-on-one meetings on Tuesday, March

SOUTH SAN FRANCISCO, Calif., and ALBANY, Ga., and WASHINGTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK), together with The Mended Hearts, Inc. and WomenHeart: The National Coalition for Women with Heart Disease, today announced the launch of ENACT: Empower, Navigate, Activate for Clinical Trials, an initiative designed to champion greater awareness and engagement in cardiovascular clinical trials by reducing barriers, increasing support and empowering patients in groups historically underrepresented in clinical research, including people of color and women to confidently navigate the clinical trial experience from start to finish. ENACT is a joint initiativ

SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 10:40 AM Eastern Time. Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event. About Cytokinetics Cytokinetics is a late-stage, sp

SOUTH SAN FRANCISCO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 7:30 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco, CA. Interested parties may access the live webcasts of the presentation by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event. About Cytokinetics Cytokinet

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the company is scheduled to participate in the following investor conferences in November: UBS BioPharma Conference on Wednesday, November 8, 2023 at 1:00 PM Eastern Time in a fireside chat with Fady I. Malik, Executive Vice President of Research & Development, and Andrew Callos, Executive Vice President, Chief Commercial Officer, at the Fontainebleau Miami Beach in Miami Beach, FL.Truist Securities BioPharma Symposium on Thursday, November 9, 2023 at 10:45 AM Eastern Time in a panel discussion, entitled "Muscle Matters: Innovative Approaches to Targeting Cardiac &

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the company is scheduled to participate in the following investor conferences in September: Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023 at 8:00 AM Eastern Time in a fireside chat with Robert I. Blum, President and Chief Executive Officer, and Fady I. Malik, Executive Vice President of Research & Development, at the Sheraton New York Times Square Hotel in New York, NY.H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023 at 8:30 AM Eastern Time in a presentation with Robert I. Blum, Presiden

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM), a Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM), is open to enrollment. Aficamten is a next-in-class cardiac myosin inhibitor in development for the potential treatment of HCM. "As the first Phase 3 clinical trial of aficamten in non-obstructive hypertrophic cardiomyopathy, ACACIA-HCM represents an important advancement in the development program for aficamten alongside our two on

First Phase 3 Trial Evaluating Monotherapy with a Cardiac Myosin Inhibitor Compared to Monotherapy with a Beta Blocker in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM), a Phase 3 clinical trial comparing aficamten as monotherapy to metoprolol as monotherapy in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), is open to enrollment. Aficamten is a next-in-class cardiac myosin inhibitor in development for the potential treatment of

SOUTH SAN FRANCISCO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the company is scheduled to participate in the following investor conferences: Jefferies Healthcare Conference: Robert I. Blum, President and Chief Executive Officer, and Andrew Callos, Executive Vice President and Chief Commercial Officer, will participate in a fireside chat on Thursday, June 8, 2023 at 9:30 AM Eastern Time at the Marriott Marquis in New York, NY.Goldman Sachs 44th Annual Global Healthcare Conference: Robert I. Blum, President and Chief Executive Officer, and Fady I. Malik, Executive Vice President of Research & Development, will participate in a f

SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 9:00 AM Eastern Time at the New York Hilton Midtown in New York, NY. Interested parties may access the live webcast of this fireside chat by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event. About Cytokinetics Cytokinetics is a la

SOUTH SAN FRANCISCO, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2023 at 10:00 AM Eastern Time. Interested parties may access the live webcast of this fireside chat by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event. About Cytokinetics Cytokinetics is a late-stage biopharmaceutical compa

SOUTH SAN FRANCISCO, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the company is scheduled to participate in the following investor conferences: Oppenheimer 33rd Annual Healthcare Conference: Robert I. Blum, President and Chief Executive Officer, will present virtually on Monday, March 13, 2023 at 10:00 AM Eastern Time.Barclays Global Healthcare Conference: Robert I. Blum, President and Chief Executive Officer, will participate in a Fireside Chat on Wednesday, March 15, 2023 at 3:35 PM Eastern Time at the Loews Miami South Beach Hotel in Miami Beach, FL.Jefferies 2023 Biotech on the Bay Summit: Management will participate in one-

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:00 AM Pacific Time at the Westin St. Francis Hotel in San Francisco. Interested parties may access the live webcast of this presentation by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Presentations page within the Investors & Media section of Cytokinetics' website for 30 days following the conclusion of the e

SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the Data Monitoring Committee (DMC) for COURAGE-ALS (Clinical Outcomes Using Reldesemtiv on ALSFRS-R in a Global Evaluation in ALS), recently convened to conduct the first planned interim analysis of this ongoing Phase 3 clinical trial which assessed for the potential of futility. The DMC reviewed unblinded data from COURAGE-ALS and recommended that conduct of the clinical trial of reldesemtiv continue. Reldesemtiv is a fast skeletal muscle troponin activator (FSTA) in clinical development for the potential treatment of amyotrophic lateral sclerosis (ALS). The first

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the company is scheduled to participate in the following investor conferences: Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022 at 8:10 AM ET in a fireside chat with Fady I. Malik, M.D., Ph.D., Executive Vice President of Research and Development, and Andrew Callos, Chief Commercial Officer, at the Sheraton New York.H.C. Wainwright 24th Annual Global Investment Conference on Tuesday, September 13, 2022 at 12:30 PM ET in a presentation with Fady I. Malik, M.D., Ph.D., Executive Vice President of Research and Development, at the L

SOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in the following investor conferences: Jefferies Healthcare Conference on Thursday, June 9, 2022 at 10:00 AM ET in a presentation at the Marriott Marquis Hotel in New York CityGoldman Sachs 43rd Annual Healthcare Conference on Monday, June 13, 2022 at 2:40 PM PT in a fireside chat at the Terranea Resort in Rancho Palos VerdesJMP Securities Life Sciences Conference on Wednesday, June 15, 2022 at 3:00 PM ET in a fireside chat at the Lotte New York Palace in New York City Intere

SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present virtually at the 2022 H.C. Wainwright Global Life Sciences Conference taking place May 23-26, 2022. The presentation will be available for on-demand viewing beginning Tuesday, May 24, 2022 at 7:00 AM ET. Interested parties may access the pre-recorded presentation by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The webcast replay will be archived on the Presentations page within the Investors & Media section of Cytokinetics' website for 90 days

SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 11:00 AM ET. Interested parties may access the live webcast of this fireside chat by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The webcast replay will be archived on the Presentations page within the Investors & Media section of Cytokinetics' website for 90 days following the conclusion of the event. About Cytokinetics Cytokin

SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the virtual Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 11:20 am ET and participate in a fireside chat at the Barclays Global Healthcare Conference on Wednesday, March 16, 2022 at 11:45 am ET at the Loews Miami Beach Hotel in Miami Beach. Interested parties may access the on-demand and live webcasts of the presentation and fireside chat by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The replay of each pres

SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the opening of enrollment in Cohort 4 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), an ongoing Phase 2 clinical trial of aficamten, an investigational next-generation cardiac myosin inhibitor in development for the potential treatment of hypertrophic cardiomyopathy (HCM). Cohort 4 will enroll patients with non-obstructive hypertrophic cardiomyopathy. "Approximately one third of people with HCM have non-obstructive HCM, and while they do not have left ventricular outflow tract obstruction, they still have considerable

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), a Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), is open to enrollment. Aficamten is a next-generation cardiac myosin inhibitor in development for the potential treatment of HCM. SEQUOIA-HCM builds on the positive results from REDWOOD-HCM, a Phase 2 clinical trial of aficamten, that demonstrated that treatment with aficamten for 10 weeks resulted in reductions from baseline compared to placebo in th

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 4:30 pm ET. Interested parties may access the live webcast of this presentation by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Presentations page within the Investors & Media section of Cytokinetics' website for 30 days following the conclusion of the event. About Cytokinetics Cytokinetics is a la

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference taking place November 30, 2021 to December 2, 2021. The pre-recorded fireside chat will be available for on-demand viewing beginning November 22, 2021 at 10:00 AM ET. Interested parties may access it by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. A replay of the fireside chat will be archived on the Presentations page within the Investors & Media section of

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in the following investor conferences in September: H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13, 2021 at 12:00 PM EDT in a virtual presentation available for on-demand viewingMorgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021 at 11:45 AM EDT in a virtual fireside chatCantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 3:20 PM EDT in a virtual presentation Interested parties may access t

SOUTH SAN FRANCISCO, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in three virtual fireside chats at the following investor conferences: 42nd Annual Goldman Sachs Healthcare Conference on Wednesday, June 9, 2021 at 3:00 PM EDTJMP Securities Life Sciences Conference on Wednesday, June 16, 2021 at 4:00 PM EDTRaymond James Human Health Innovation Conference on Monday, June 21, 2021 at 2:00 PM EDT Interested parties may access the live webcasts of each presentation by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetic

SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 3:00 PM ET. Interested parties may access the live webcast of this presentation by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The webcast replay will be archived on the Presentations page within the Investors & Media section of Cytokinetics' website for 90 days following the conclusion of the event. About Cytokinetics Cy

SOUTH SAN FRANCISCO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021 and participate in a fireside chat at the virtual Barclays Global Healthcare Conference on March 11, 2021 at 9:45 AM ET. Interested parties may access the pre-recorded presentation from the H.C. Wainwright Global Life Sciences Conference and the live webcast of the fireside chat from the Barclays Global Healthcare Conference by visiting the Investors & Media section of the Cytokinetics website a

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference taking place January 11-14, 2021. The presentation will be available for on-demand listening beginning January 11, 2021 at 6:00 AM Eastern Time. Interested parties may access the recorded webcast of this presentation by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The webcast will be archived on the Presentations page within the Investors & Media section